In a sneak peek at athenahealth’s plans for the HIMSS23 Conference and Exhibition this April, CEO Bob Segert said that a key highlight will be the company’s focus on improving the patient creating a consumer-grade patient experience – including a showcase of new features.
“A lot of times folks…
Source: Healthcareitnews.com and Read More
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
